does the cariprazine label advise contraception during treatment and for 10 weeks after?
“Its manufacturer advises highly effective contraception during treatment.”
a host said on Psychopharmacology and Psychiatry Updates, 2026-10-28, at 11:01. hear it in context → the speaker cited: the manufacturer.
the episode: First-Episode Psychosis in Women (at 11:01). we link the show's own page; we do not re-host audio.
first, the part that holds
this is right. the european product information for cariprazine says female patients who could become pregnant must use highly effective contraception during treatment and for at least 10 weeks after the last dose.
what we found when we went and looked
we read the EMA-approved summary of product characteristics for cariprazine. section 4.6 says: "Female patients of child-bearing potential must use highly effective contraceptive methods during treatment and for at least 10 weeks following the last dose." the same section says the drug is "not recommended during pregnancy and in women of childbearing potential not using effective contraception," and gives the reason for the 10 weeks: "the slow elimination of active moieties." one thing listeners outside europe should know: the US prescribing information on DailyMed (revised 12/2025) has no contraception advice. it has no section 8.3 on females of reproductive potential, and its pregnancy section only says that based on animal data the drug "may cause fetal harm."
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| the manufacturer's product information advises highly effective contraception during cariprazine treatment | confirmed | EU SmPC section 4.6: female patients of child-bearing potential 'must use highly effective contraceptive methods during treatment.' the wording is mandatory ('must'), not just a suggestion. the source is the EU label, issued by the marketing authorisation holder and approved by EMA. [1] |
| the contraception advice continues for 10 weeks after stopping | confirmed | EU SmPC section 4.6 says 'for at least 10 weeks following the last dose' and repeats it: 'After discontinuation of cariprazine treatment contraception should be used for at least 10 weeks due to the slow elimination of active moieties.' the label's wording is 'at least' 10 weeks, so 10 weeks is the minimum, not a fixed period. [1] |
| the US prescribing information carries the same contraception advice | false | the US label (DailyMed, revised 12/2025) has no section 8.3 on females and males of reproductive potential and no contraception advice anywhere we read. section 8.1 says only 'Based on animal data, VRAYLAR may cause fetal harm,' notes that the metabolite DDCAR 'has been detected in adult patients up to 12 weeks after discontinuation,' and points to a pregnancy exposure registry. [2] |
| the long washout reflects how long the drug's active metabolite stays in the body | confirmed | US label section 12.3: the half-life of DDCAR is about 1 to 3 weeks, it takes about 4 weeks for DDCAR exposure to fall by about 90%, and after a single 1 mg dose DDCAR 'remained detectable 8 weeks post-dose.' the EU SmPC gives slow elimination as the reason for the 10 weeks. [1][2] |
| cariprazine makes hormonal contraception less effective, which is why the warning exists | false | EU SmPC section 4.5: '28 days of treatment with cariprazine at 6 mg daily had no clinically relevant effect on the pharmacokinetics of oral contraceptives (ethinylestradiol and levonorgestrel).' the warning is about possible harm to a fetus (rat reproductive toxicity), not about the pill failing. [1] |
both directions
for the speaker: the EU summary of product characteristics says it twice, in section 4.6, in mandatory language: highly effective contraception during treatment and for at least 10 weeks after the last dose. it also says cariprazine is not recommended in pregnancy or in women of childbearing potential who are not using effective contraception. the pharmacokinetics explain the long tail. the major active metabolite has a half-life of about 1 to 3 weeks, and the US label says it was detected in patients up to 12 weeks after stopping. both labels describe animal reproductive toxicity: in rats, malformations, lower pup survival and developmental delays at exposures below the maximum human dose.
against: "its manufacturer advises" is true of the european label and not of the american one. the US prescribing information, revised 12/2025, has no contraception recommendation and no reproductive-potential section. it gives a fetal-harm statement based on animal data and a pregnancy registry. so a US listener who checks their own package insert will not find this advice there. the claim sentence also says "10 weeks", while the label says "at least 10 weeks", which is a floor, not a set period. and neither label has human data showing harm. the US label says there are no available data on use in pregnant women, and the EU label says there are "no or limited" data. the warning comes from animal findings and slow elimination, not from observed human birth defects.
what this cannot say
we read two labels: the EMA product information and one US prescribing information on DailyMed. we did not check labels in the UK, canada, australia or other countries, and they may word this differently. a label is a regulatory instruction, not evidence of how risky the drug is in human pregnancy. both labels say human pregnancy data are absent or limited. we can't tell from the show which country's label the host had in mind. labels also get revised, so this reflects the versions we fetched on 2026-10-29. none of this is advice to start, stop or change a medication. questions about pregnancy plans and contraception belong with a prescriber.
sources, each one fetched and read
- European Medicines Agency. cariprazine hard capsules, EPAR product information, Annex I summary of product characteristics, sections 4.5 and 4.6 What we read there: section 4.6: 'Women of childbearing potential must be advised to avoid pregnancy while on [cariprazine]. Female patients of child-bearing potential must use highly effective contraceptive methods during treatment and for at least 10 weeks following the last dose.' also: 'After discontinuation of cariprazine treatment contraception should be used for at least 10 weeks due to the slow elimination of active moieties.' section 4.5: 28 days of cariprazine 6 mg had no clinically relevant effect on oral contraceptive pharmacokinetics. Fetched 2026-10-29 (HTTP 200). https://www.ema.europa.eu/en/documents/product-information/reagila-epar-product-information_en.pdf
- US National Library of Medicine, DailyMed. cariprazine capsules, full prescribing information, revised 12/2025, sections 8.1 and 12.3 What we read there: section 8 lists 8.1 pregnancy, 8.2 lactation, then 8.4 onward. there is no 8.3 and no contraception advice. 8.1: 'Based on animal data, [cariprazine] may cause fetal harm'; 'DDCAR, has been detected in adult patients up to 12 weeks after discontinuation.' 12.3: DDCAR half-life about 1 to 3 weeks, and after a single 1 mg dose DDCAR 'remained detectable 8 weeks post-dose.' Fetched 2026-10-29 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f&type=pdf&name=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam